**Executive Summary:**

An explosion of clinical trials occurred to help prevent spread, and develop vaccines during the 2020 Covid-19 pandemic. Given Covid-19’s current impact, our team decided to analyze the publicly available trial data to better understand the relationship between the number of trials by year, country, specific trial site, symptom(s) studied, and sponsor. In addition, our team also summarized enrollment numbers in the trials, as well as target age and gender data among trial subjects. Our team obtained information from the ClinicalTrials.gov API in July 2020 and once we cleaned the data, were able to begin developing the relationships outlined above. The major findings were:

* Clinical trials though broad in scope tended to focus more on the respiratory symptoms
* The number of trials exploded 700x in 2020, occurs in greater numbers in developed nations, and run more often than not by independent organizations in collaboration with one another.
* The trials focused on most elder patients with <100 participants in vast majority of the trials

Note that the world is in constant flux due to the evolving nature of Covid-19 and further R&D (lab and/or clinical trial data), public policies, and other relevant might come to light that alter the nature of future clinical trials. As a result, these reported findings are to be treated just as a snapshot in time.